PDP-Desonide: Formulary list price $0.2857/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2857 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43536 · Verify on the e-Formulary ↗ (DIN 02229315)
Source record
DIN 02229315: PDP-Desonide
Raw flags: sec3=Y
Item: 840600043; group id 842; item number 2051; lccId None; manufacturer id PEN
Source form: Cr; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.2857; ministry $0.2857
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229315
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43536Interchangeable products
Tridesilon · DIN 02154862 · not recorded
Shortage status: anticipated shortage (last updated 2026-08-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02229315
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PDP-Desonide · DIN 02229323 · 0.05% · Oint
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PDP-Desonide · DIN 02229323
Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1997-04-10
Health Canada: Marketed since 2014-08-06 · brand PDP-DESONIDE · ATC D07AB08 DESONIDE · form Ointment · route Topical · ingredients DESONIDE 0.05 %/W/W · company Pendopharm division of pharmascience inc · schedule Prescription
PDP-Desonide: Formulary list price $0.2853/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2853 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43537 · Verify on the e-Formulary ↗ (DIN 02229323)
Source record
DIN 02229323: PDP-Desonide
Raw flags: sec3=Y
Item: 840600045; group id 842; item number 2052; lccId None; manufacturer id PEN
Source form: Oint; strength: 0.05%
Recorded listing: General benefit
Source prices (unrounded): $0.2853; ministry $0.2853
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229323
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43537Interchangeable products
Tridesilon · DIN 02154870 · not recorded
Shortage status: active shortage (reported 2024-02-05, estimated to end 2026-09-28, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02229323
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tridesilon · DIN 02154862 · 0.05% · Cr
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.Discontinued 2023-09-29 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tridesilon · DIN 02154862
Manufacturer: Clay-Park Labs Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2023-09-29 · brand TRIDESILON 0.05% DESONIDE CREAM · ATC D07AB08 DESONIDE · form Cream · route Topical · ingredients DESONIDE 0.05 % · company Perrigo international · schedule Prescription
Tridesilon: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=33930 · Verify on the e-Formulary ↗ (DIN 02154862)
Source record
DIN 02154862: Tridesilon
Raw flags: notABenefit=Y, sec3=Y
Item: 840600043; group id 842; item number 2051; lccId None; manufacturer id CPL
Source form: Cr; strength: 0.05%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02154862
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=33930Interchangeable products
PDP-Desonide · DIN 02229315 · $0.2857
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02154862
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Tridesilon · DIN 02154870 · 0.05% · Oint
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.Discontinued 2023-09-29 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tridesilon · DIN 02154870
Manufacturer: Clay-Park Labs Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2023-09-29 · brand TRIDESILON 0.05% DESONIDE OINTMENT · ATC D07AB08 DESONIDE · form Ointment · route Topical · ingredients DESONIDE 0.05 % · company Perrigo international · schedule Prescription
Tridesilon: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=33931 · Verify on the e-Formulary ↗ (DIN 02154870)
Source record
DIN 02154870: Tridesilon
Raw flags: notABenefit=Y, sec3=Y
Item: 840600045; group id 842; item number 2052; lccId None; manufacturer id CPL
Source form: Oint; strength: 0.05%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02154870
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=33931Interchangeable products
PDP-Desonide · DIN 02229323 · $0.2853
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02154870
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
BUDESONIDE
Form:
16 of 16 products shown
6 general benefit · 9 Limited Use · 1 not a benefit
Other products in the same Health Canada class (D07A, D07AB) — coverage varies; not interchangeable
Triamcinolone acetonide (Kenalog): general benefit, Not a benefit
Amcinonide (Cyclocort): general benefit, Not a benefit
Beclomethasone dipropionate (Propaderm): general benefit
Betamethasone dipropionate (Diprosone): general benefit
Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
8 more in the class list below
Pulmicort Nebuamp · DIN 02229099 · 0.125mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Pulmicort Nebuamp (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Pulmicort Nebuamp · DIN 02229099
Manufacturer: AstraZeneca; listing date 1998-12-31
Health Canada: Marketed since 2000-01-29 · brand PULMICORT NEBUAMP 0.125 MG/ML · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.125 MG/ML · company Astrazeneca canada inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43511 · Verify on the e-Formulary ↗ (DIN 02229099)
Source record
DIN 02229099: Pulmicort Nebuamp
Raw flags: sec12=Y, sec3=Y
Item: 680400072; group id 704; item number 1737; lccId 00107; manufacturer id AZC
Source form: Inh Susp; strength: 0.125mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2778; ministry $0.1143
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229099
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43511Interchangeable products
Taro-Budesonide · DIN 02494264 · $0.1143
Teva-Budesonide · DIN 02465949 · $0.1143
Shortage status: resolved shortage (ended 2023-04-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02229099
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Budesonide · DIN 02494264 · 0.125mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Budesonide · DIN 02494264
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2021-07-30
Health Canada: Marketed since 2021-06-04 · brand TARO-BUDESONIDE · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.125 MG/ML · company Taro pharmaceuticals inc · schedule Prescription
Taro-Budesonide: Formulary list price $0.1143/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1143 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98429 · Verify on the e-Formulary ↗ (DIN 02494264)
Source record
DIN 02494264: Taro-Budesonide
Raw flags: sec12=Y, sec3=Y
Item: 680400072; group id 704; item number 1737; lccId 00107; manufacturer id TAR
Source form: Inh Susp; strength: 0.125mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.1143; ministry $0.1143
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494264
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98429Interchangeable products
Pulmicort Nebuamp · DIN 02229099 · $0.1143
Teva-Budesonide · DIN 02465949 · $0.1143
Shortage status: active shortage (reported 2022-04-14, last updated 2026-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02494264
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Budesonide · DIN 02465949 · 0.125mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Budesonide · DIN 02465949
Manufacturer: Teva Canada Limited; listing date 2018-04-30
Health Canada: Marketed since 2017-11-08 · brand TEVA-BUDESONIDE · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.125 MG/ML · company Teva canada limited · schedule Prescription
Teva-Budesonide: Formulary list price $0.1143/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1143 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95417 · Verify on the e-Formulary ↗ (DIN 02465949)
Source record
DIN 02465949: Teva-Budesonide
Raw flags: sec12=Y, sec3=Y
Item: 680400072; group id 704; item number 1737; lccId 00107; manufacturer id TEV
Source form: Inh Susp; strength: 0.125mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.1143; ministry $0.1143
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02465949
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95417Interchangeable products
Pulmicort Nebuamp · DIN 02229099 · $0.1143
Taro-Budesonide · DIN 02494264 · $0.1143
Shortage status: resolved shortage (ended 2025-12-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02465949
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Pulmicort Nebuamp · DIN 01978918 · 0.25mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Pulmicort Nebuamp (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Pulmicort Nebuamp · DIN 01978918
Manufacturer: AstraZeneca; listing date 1996-10-01
Health Canada: Marketed since 2000-01-29 · brand PULMICORT NEBUAMP 0.25 MG/ML · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.25 MG/ML · company Astrazeneca canada inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13191 · Verify on the e-Formulary ↗ (DIN 01978918)
Source record
DIN 01978918: Pulmicort Nebuamp
Raw flags: sec12=Y, sec3=Y
Item: 680400077; group id 704; item number 1738; lccId 00107; manufacturer id AZC
Source form: Inh Susp; strength: 0.25mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.5560; ministry $0.2395
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01978918
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13191Interchangeable products
Taro-Budesonide · DIN 02494272 · $0.2395
Teva-Budesonide · DIN 02535416 · $0.2395
Shortage status: resolved shortage (ended 2023-01-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01978918
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Budesonide · DIN 02494272 · 0.25mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Budesonide · DIN 02494272
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2021-07-30
Health Canada: Marketed since 2021-06-04 · brand TARO-BUDESONIDE · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.25 MG/ML · company Taro pharmaceuticals inc · schedule Prescription
Taro-Budesonide: Formulary list price $0.2395/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2395 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98430 · Verify on the e-Formulary ↗ (DIN 02494272)
Source record
DIN 02494272: Taro-Budesonide
Raw flags: sec12=Y, sec3=Y
Item: 680400077; group id 704; item number 1738; lccId 00107; manufacturer id TAR
Source form: Inh Susp; strength: 0.25mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2395; ministry $0.2395
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494272
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98430Interchangeable products
Pulmicort Nebuamp · DIN 01978918 · $0.2395
Teva-Budesonide · DIN 02535416 · $0.2395
Shortage status: active shortage (reported 2025-06-11, last updated 2026-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02494272
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Budesonide · DIN 02535416 · 0.25mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Budesonide · DIN 02535416
Manufacturer: Teva Canada Limited; listing date 2026-06-30
Health Canada: Marketed since 2026-03-31 · brand TEVA-BUDESONIDE · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.25 MG/ML · company Teva canada limited · schedule Prescription
Teva-Budesonide: Formulary list price $0.2395/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2395 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102427 · Verify on the e-Formulary ↗ (DIN 02535416)
Source record
DIN 02535416: Teva-Budesonide
Raw flags: sec12=Y, sec3=Y
Item: 680400077; group id 704; item number 1738; lccId 00107; manufacturer id TEV
Source form: Inh Susp; strength: 0.25mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2395; ministry $0.2395
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535416
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102427Interchangeable products
Pulmicort Nebuamp · DIN 01978918 · $0.2395
Taro-Budesonide · DIN 02494272 · $0.2395
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02535416
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Pulmicort Nebuamp · DIN 01978926 · 0.5mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Pulmicort Nebuamp (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Pulmicort Nebuamp · DIN 01978926
Manufacturer: AstraZeneca; listing date 1996-10-01
Health Canada: Marketed since 2002-12-15 · brand PULMICORT NEBUAMP 0.5 MG/ML · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.5 MG/ML · company Astrazeneca canada inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13190 · Verify on the e-Formulary ↗ (DIN 01978926)
Source record
DIN 01978926: Pulmicort Nebuamp
Raw flags: sec12=Y, sec3=Y
Item: 680400078; group id 704; item number 1739; lccId 00107; manufacturer id AZC
Source form: Inh Susp; strength: 0.5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.1095; ministry $0.4559
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01978926
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13190Interchangeable products
Taro-Budesonide · DIN 02494280 · $0.4559
Teva-Budesonide · DIN 02465957 · $0.4559
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01978926
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Budesonide · DIN 02494280 · 0.5mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Budesonide · DIN 02494280
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2021-07-30
Health Canada: Marketed since 2021-06-04 · brand TARO-BUDESONIDE · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.5 MG/ML · company Taro pharmaceuticals inc · schedule Prescription
Taro-Budesonide: Formulary list price $0.4559/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4559 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98431 · Verify on the e-Formulary ↗ (DIN 02494280)
Source record
DIN 02494280: Taro-Budesonide
Raw flags: sec12=Y, sec3=Y
Item: 680400078; group id 704; item number 1739; lccId 00107; manufacturer id TAR
Source form: Inh Susp; strength: 0.5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4559; ministry $0.4559
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494280
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98431Interchangeable products
Pulmicort Nebuamp · DIN 01978926 · $0.4559
Teva-Budesonide · DIN 02465957 · $0.4559
Shortage status: active shortage (reported 2022-04-14, last updated 2026-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02494280
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Budesonide · DIN 02465957 · 0.5mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Budesonide · DIN 02465957
Manufacturer: Teva Canada Limited; listing date 2018-03-29
Health Canada: Marketed since 2017-11-08 · brand TEVA-BUDESONIDE · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.5 MG/ML · company Teva canada limited · schedule Prescription
Teva-Budesonide: Formulary list price $0.4559/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4559 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95418 · Verify on the e-Formulary ↗ (DIN 02465957)
Source record
DIN 02465957: Teva-Budesonide
Raw flags: sec12=Y, sec3=Y
Item: 680400078; group id 704; item number 1739; lccId 00107; manufacturer id TEV
Source form: Inh Susp; strength: 0.5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4559; ministry $0.4559
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02465957
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95418Interchangeable products
Pulmicort Nebuamp · DIN 01978926 · $0.4559
Taro-Budesonide · DIN 02494280 · $0.4559
Shortage status: resolved shortage (ended 2025-11-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02465957
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Uceris: Formulary list price $99.9600/unit (unit not stated in source; not the patient's cost)
Ministry pays: $99.9600 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98785 · Verify on the e-Formulary ↗ (DIN 02498057)
Source record
DIN 02498057: Uceris
Raw flags: sec3=Y
Item: 564000142; group id 673; item number 1682; lccId None; manufacturer id BHC
Source form: Rectal Foam-14 Act Canister; strength: 2mg/Act
Recorded listing: General benefit
Source prices (unrounded): $99.9600; ministry $99.9600
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498057
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98785
Shortage status: resolved shortage (ended 2025-08-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498057
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Rhinocort Aqua · DIN 02231923 · 64mcg/Metered Dose · Nas Sp-120 Dose Pk
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Rhinocort Aqua · DIN 02231923
Manufacturer: McNeil Consumer Products Co.; listing date 1998-12-31
Health Canada: Marketed since 2026-03-09 · brand RHINOCORT AQUA · ATC R01AD05 BUDESONIDE · form Spray (metered-dose) · route Nasal · ingredients BUDESONIDE 64 MCG/ACT · company Kenvue canada inc. · schedule Prescription
Rhinocort Aqua: Formulary list price $11.0400/unit (unit not stated in source; not the patient's cost)
Ministry pays: $11.0400 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51375 · Verify on the e-Formulary ↗ (DIN 02231923)
Source record
DIN 02231923: Rhinocort Aqua
Raw flags: sec3=Y
Item: 520800039; group id 591; item number 1548; lccId None; manufacturer id MCL
Source form: Nas Sp-120 Dose Pk; strength: 64mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $11.0400; ministry $11.0400
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231923
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51375
Shortage status: resolved shortage (ended 2018-09-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231923
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Budesonide AQ · DIN 02230648 · 100mcg/Metered Dose · Nas Sp-165 Dose Pk
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Budesonide AQ · DIN 02230648
Manufacturer: Mylan Pharmaceuticals ULC; listing date 1998-12-31
Health Canada: Marketed since 2010-06-24 · brand MYLAN-BUDESONIDE AQ · ATC R01AD05 BUDESONIDE · form Spray (metered-dose) · route Nasal · ingredients BUDESONIDE 100 MCG/ACT · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Budesonide AQ: Formulary list price $12.7400/unit (unit not stated in source; not the patient's cost)
Ministry pays: $12.7400 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49895 · Verify on the e-Formulary ↗ (DIN 02230648)
Source record
DIN 02230648: Mylan-Budesonide AQ
Raw flags: sec3=Y
Item: 520800032; group id 591; item number 1549; lccId None; manufacturer id MYL
Source form: Nas Sp-165 Dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $12.7400; ministry $12.7400
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230648
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49895Interchangeable products
Rhinocort Aqua · DIN 01974432 · not recorded
Shortage status: resolved shortage (ended 2025-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02230648
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Pulmicort Turbuhaler: Formulary list price $39.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $39.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10667 · Verify on the e-Formulary ↗ (DIN 00852074)
Source record
DIN 00852074: Pulmicort Turbuhaler
Raw flags: sec3=Y
Item: 680400051; group id 705; item number 1740; lccId None; manufacturer id AZC
Source form: Pd Inh-200 Dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $39.0000; ministry $39.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00852074
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10667
Shortage status: resolved shortage (ended 2022-02-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00852074
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Pulmicort Turbuhaler: Formulary list price $79.7600/unit (unit not stated in source; not the patient's cost)
Ministry pays: $79.7600 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10666 · Verify on the e-Formulary ↗ (DIN 00851752)
Source record
DIN 00851752: Pulmicort Turbuhaler
Raw flags: sec3=Y
Item: 680400052; group id 705; item number 1741; lccId None; manufacturer id AZC
Source form: Pd Inh-200 Dose Pk; strength: 200mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $79.7600; ministry $79.7600
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00851752
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10666
Shortage status: resolved shortage (ended 2022-02-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00851752
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Pulmicort Turbuhaler: Formulary list price $116.4200/unit (unit not stated in source; not the patient's cost)
Ministry pays: $116.4200 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12182 · Verify on the e-Formulary ↗ (DIN 00851760)
Source record
DIN 00851760: Pulmicort Turbuhaler
Raw flags: sec3=Y
Item: 680400053; group id 705; item number 1742; lccId None; manufacturer id AZC
Source form: Pd Inh-200 Dose Pk; strength: 400mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $116.4200; ministry $116.4200
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00851760
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12182
Shortage status: resolved shortage (ended 2022-03-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00851760
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Rhinocort Aqua · DIN 01974432 · 100mcg/Metered Dose · Nas Sp-165 Dose Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-07-29 — choose a marketed DIN from the same-category list.Discontinued 1999-07-29 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-07-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1999-07-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Rhinocort Aqua · DIN 01974432
Manufacturer: Astra Pharma Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 1999-07-29 · brand RHINOCORT AQUA 100MCG · ATC R01AD05 BUDESONIDE · form Metered-dose aerosol · route Nasal · ingredients BUDESONIDE 100 MCG/ACT · company Astra pharma inc. · schedule Prescription
Rhinocort Aqua: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13962 · Verify on the e-Formulary ↗ (DIN 01974432)
Source record
DIN 01974432: Rhinocort Aqua
Raw flags: notABenefit=Y, sec3=Y
Item: 520800032; group id 591; item number 1549; lccId None; manufacturer id AST
Source form: Nas Sp-165 Dose Pk; strength: 100mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01974432
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13962Interchangeable products
Mylan-Budesonide AQ · DIN 02230648 · $12.7400
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01974432
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1999-07-29 — choose a marketed DIN from the same-category list.
BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE
All strengths: Limited Use — Reason for Use code 330 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 330 required
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (D07A, D07AB) — coverage varies; not interchangeable
Triamcinolone acetonide (Kenalog): general benefit, Not a benefit
Amcinonide (Cyclocort): general benefit, Not a benefit
Beclomethasone dipropionate (Propaderm): general benefit
Betamethasone dipropionate (Diprosone): general benefit
Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330
For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Symbicort 100 Turbuhaler · DIN 02245385
Manufacturer: AstraZeneca; listing date 2003-01-30
Health Canada: Marketed since 2002-02-08 · brand SYMBICORT 100 TURBUHALER · ATC R03AK07 FORMOTEROL AND BUDESONIDE, R03AK07 FORMOTEROL AND BUDESONIDE · form Powder · route Inhalation · ingredients FORMOTEROL FUMARATE DIHYDRATE 6 MCG/ACT, BUDESONIDE 100 MCG/ACT · company Astrazeneca canada inc · schedule Prescription
Symbicort 100 Turbuhaler: Formulary list price $79.8500/unit (unit not stated in source; not the patient's cost)
Ministry pays: $79.8500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69428 · Verify on the e-Formulary ↗ (DIN 02245385)
Source record
DIN 02245385: Symbicort 100 Turbuhaler
Raw flags: sec12=Y, sec3=Y
Item: 121200087; group id 220; item number 0397; lccId 00032; manufacturer id AZC
Source form: Pd Inh-120 Dose Pk; strength: 100mcg/6mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $79.8500; ministry $79.8500
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245385
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69428
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245385
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330
For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Symbicort 200 Turbuhaler · DIN 02245386
Manufacturer: AstraZeneca; listing date 2003-01-30
Health Canada: Marketed since 2002-02-08 · brand SYMBICORT 200 TURBUHALER · ATC R03AK07 FORMOTEROL AND BUDESONIDE, R03AK07 FORMOTEROL AND BUDESONIDE · form Powder · route Inhalation · ingredients BUDESONIDE 200 MCG/ACT, FORMOTEROL FUMARATE DIHYDRATE 6 MCG/ACT · company Astrazeneca canada inc · schedule Prescription
Symbicort 200 Turbuhaler: Formulary list price $103.7500/unit (unit not stated in source; not the patient's cost)
Ministry pays: $103.7500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69429 · Verify on the e-Formulary ↗ (DIN 02245386)
Source record
DIN 02245386: Symbicort 200 Turbuhaler
Raw flags: sec12=Y, sec3=Y
Item: 121200088; group id 220; item number 0398; lccId 00032; manufacturer id AZC
Source form: Pd Inh-120 Dose Pk; strength: 200mcg/6mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $103.7500; ministry $103.7500
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245386
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69429
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245386
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 638 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 638 required
Write on scriptLU code 638 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 638
Reason for Use code 638
For the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA).
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Breztri Aerosphere · DIN 02518058
Manufacturer: AstraZeneca; listing date 2022-10-31
Health Canada: Marketed since 2024-01-05 · brand BREZTRI AEROSPHERE · ATC R03AL11 FORMOTEROL, GLYCOPYRRONIUM BROMIDE AND BUDESONIDE, R03AL11 FORMOTEROL, GLYCOPYRRONIUM BROMIDE AND BUDESONIDE, R03AL11 FORMOTEROL, GLYCOPYRRONIUM BROMIDE AND BUDESONIDE · form Aerosol (metered-dose) · route Inhalation · ingredients GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE) 7.2 MCG/ACT, FORMOTEROL FUMARATE DIHYDRATE 5 MCG/ACT, BUDESONIDE 160 MCG/ACT · company Astrazeneca canada inc · schedule Prescription
Breztri Aerosphere: Formulary list price $127.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $127.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100738 · Verify on the e-Formulary ↗ (DIN 02518058)
Source record
DIN 02518058: Breztri Aerosphere
Raw flags: sec12=Y, sec3=Y
Item: 121200121; group id 221; item number 0399; lccId 00385; manufacturer id AZC
Source form: Metered Dose Inh-120 Dose Pk; strength: 160mcg & 7.2mcg & 5mcg/Act
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $127.0000; ministry $127.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02518058
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100738
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02518058
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE
Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE, SALBUTAMOL
12:12 Sympathomimetic (Adrenergic) Agents
Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered
Matched class: 52:08 Anti-Inflammatory Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: DEXAMETHASONE, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, KETOROLAC TROMETHAMINE, LODOXAMIDE TROMETHAMINE
Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, PREDNISOLONE ACETATE
52:08 Anti-Inflammatory Agents
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:08
and 2 more
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered
Matched class: 56:40 Miscellaneous G.I. Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE
Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL
56:40 Miscellaneous G.I. Drugs
· 16 products · General benefit · strengths: 10mg, 20mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40
and 10 more
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered
Matched class: 68:04 Corticosteroids
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE
Some products covered without a code (check the product listing): DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE
68:04 Corticosteroids
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04
and 5 more
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered
Matched class: 84:06 Anti-Inflammatory
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE
Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE
84:06 Anti-Inflammatory
· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint
· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06
and 5 more
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
FLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1)
Page 3 of 74
Asthma
BREO ELLIPTA 100/25 mcg and BREO ELLIPTA 200/25 mcg are indicated for the
once-daily maintenance treatment of asthma in patients aged 18 years and older with
reversible obstructive airways disease.
PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10
Product monographINDACATEROL ACETATE & MOMETASONE FUROATE · Limited Use, codes 626
1 INDICATIONS
ATECTURA BREEZHALER (indacaterol/mometasone furoate) is a combination of a long-acting beta2-
adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) indicated as a once-daily maintenance
treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive
airways disease.
PM: https://pdf.hres.ca/dpd_pm/00063537.PDF; date May 5, 2020; DIN 02498685; fetched 2026-09-10
Product monographMOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 330
1 Indications
ZENHALE® (mometasone furoate / formoterol fumarate dihydrate inhalation aerosol), is a combination
of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for:
• the treatment of asthma, in patients 12 years of age and older with reversible obstructive airway
disease.
PM: https://pdf.hres.ca/dpd_pm/00080784.PDF; date 2025-06-09; DIN 02361752; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
pdp-DESONIDE (desonide) 0.05% topical preparations are intended for use in the management
of acute or chronic dermatoses. They have been demonstrated to have anti-inflammatory activity
when used topically in:
Atopic Dermatitis
Contact Dermatitis (including Poison Ivy and Venenata)
Psoriasis
Eczema (including Nummular Eczema)
Neurodermatitis
Seborrheic Dermatitis
Lichen Simplex Chronicus (Lichen Planus)
Dyshidrosis
Acute Solar Dermatitis (Sunburn)
Statis Dermatitis
3
https://pdf.hres.ca/dpd_pm/00060564.PDF
PM date: March 26, 2021
Source product: PDP-DESONIDE; DIN 02229315; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
Patients with bronchial asthma:
In patients who require inhaled steroids;
In patients for whom a reduction of systemic glucocorticoids is desirable.
https://pdf.hres.ca/dpd_pm/00042073.PDF
PM date: November 8, 2017
Source product: PULMICORT TURBUHALER; DIN 00851752; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
Asthma
SYMBICORT TURBUHALER (budesonide and formoterol fumarate dihydrate) is indicated
for the treatment of asthma in patients 12 years and older with reversible obstructive airways
disease.
SYMBICORT TURBUHALER can be used according to three different treatment
approaches:
A. SYMBICORT TURBUHALER Anti-inflammatory Reliever Therapy: in patients
with mild persistent asthma, SYMBICORT 200 TURBUHALER is taken as needed
for relief of asthma symptoms when they occur.
SYMBICORT TURBUHALER has not been evaluated in patients whose asthma can
be managed by occasional use of a rapid onset, short duration, inhaled beta2-agonist.
B. SYMBICORT TURBUHALER Anti-inflammatory Reliever plus Maintenance
Therapy: in patients with moderate or severe asthma, SYMBICORT 100
TURBUHALER or SYMBICORT 200 TURBUHALER are taken both as daily
maintenance therapy and as needed for relief of asthma symptoms when they occur.
C. SYMBICORT TURBUHALER Maintenance Therapy: in patients with moderate
or severe asthma, SYMBICORT TURBUHALER is taken as a fixed-dose daily
COPYRIGHT 2002-2020 ASTRAZENEC…
https://pdf.hres.ca/dpd_pm/00059997.PDF
PM date: February 8, 2021
Source product: SYMBICORT 100 TURBUHALER; DIN 02245385; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
BREZTRI™ AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate dihydrate) is a
combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a
long-acting beta2-adrenergic agonist (LABA), indicated for the long-term maintenance treatment
to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and treat airflow
obstruction in patients with COPD, including chronic bronchitis and/or emphysema who are not
adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA.
BREZTRI AEROSPHERE is not indicated for the treatment of acute episodes of bronchospasm
(see General).
BREZTRI AEROSPHERE is not indicated for the treatment of asthma.
1.1 Pediatrics
Pediatrics (< 18 years of age): The safety and efficacy of BREZTRI AEROSPHERE in pediatric
patients under 18 years of age have not been established; therefore, Health Canada has not
authorized an indication for pediatric use.
1.2 Geriatrics
Geriatrics (≥ 65 years of age): No dosage adjustment is required in patients 65 years of age
and older.
https://pdf.hres.ca/dpd_pm/00074118.PDF
PM date: APR 14, 2023
Source product: BREZTRI AEROSPHERE; DIN 02518058; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
PDP-Desonide · DIN 02229323
Shortage status: active shortage (reported 2024-02-05, estimated to end 2026-09-28, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02229323
Taro-Budesonide · DIN 02494264
Shortage status: active shortage (reported 2022-04-14, last updated 2026-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02494264
Taro-Budesonide · DIN 02494272
Shortage status: active shortage (reported 2025-06-11, last updated 2026-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02494272
Taro-Budesonide · DIN 02494280
Shortage status: active shortage (reported 2022-04-14, last updated 2026-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02494280
For Tridesilon, Rhinocort Aqua: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.